Autoimmune manifestation of hepatitis C virus infection as a risk for late virological relapse after pegylated interferon and ribavirin therapy
Abstract
Introduction. We are aware of the risk of late virological relapse (LVR) years after sustained viral response (SVR) by pegylated interferon and ribavirin alfa (PegIFNa + RBV) of chronic hepatitis C viral (HCV) infection. We presented three patients with LVR, treated by PegIFNa and ribavirin 5 years after the SVR was established. Case report. We analysed 129 (38.8% female, 61.2% male, mean age 37.02 ± SD 11.99) patients treated for chronic HCV with PegIFNa + RBV, with at least 5 years from the establishment of SVR. In addition to the biochemical parameters of liver function, the qualitative HCV RNA polymerase chain reaction (PCR) and the quantitative PCR HCV RNA test were made. Five years after establishing SVR in 2.3% (3/129) of patients, the relapse of HCV infection was registered by qualitative and quantitative PCR HCV RNA assay and all of these patients had additional autoimmune diseases: vasculitis, autoimmune hepatitis, and vasculitis of central nervous system. Conclusion. The existence, but low rate of LVR HCV infection was confirmed, dominantly in patients with additional autoimmune diseases. Due to this SVR after therapy by PegIFNa + RBV should be considered as an indicator of successful HCV suppresion, not its complete eradication.
References
References
Gower E, Estes C, Blach S, Razavi-Shearer K, Razavi H. Global epi¬demiology and genotype distribution of the hepatitis C vi-rus infection. J Hepatol 2014; 61(suppl 1): 45–57.
European Association for the Study of the Liver. EASL Recommen-da¬tions on Treatment of Hepatitis C. J Hepatol 2015; 63(1): 199–236.
Morisco F, Granata R, Stroffolini T, Guarino M, Donnarumma L, Gaeta L, et al. Sustained virological response: a milestone in the treatment of chronic hepatitis C. World J Gastroenterol 2013; 19(18): 2793–8.
Swain MG, Lai M, Shiffman ML, Cooksley GW, Zeuzem S, Di-eterich DT, et al. A sustained virologic response is durable in patients with chronic hepatitis C treated with peginterferon alfa-2a and ribavirin. Gastroenterology 2010; 139(5): 1593–601.
Manns MP, Pockros PJ, Norkrans G, Smith CI, Morgan TR, Häussinger D, et al. Long-term clearance of hepatitis C virus following interferon α-2b or peginterferon α-2b, alone or in combination with ribavirin. J Viral Hepat 2013; 20(8): 524–9.
Formann E, Steindl-Munda P, Hofer H, Jessner W, Bergholz U, Gur¬guta C, et al. Long-term follow-up of chronic hepatitis C pa¬tients with sustained virological response to various forms of interferon-based anti-viral therapy. Aliment Pharmacol Ther 2006; 23(4): 507–11.
George SL, Bacon BR, Brunt EM, Mihindukulasuriya KL, Hoff-mann J, di Bisceglie AM. Clinical, virologic, histologic, and bio-chemical outcomes after successful HCV therapy: A 5-year follow-up of 150 patients. Hepatology 2009; 49(3): 729–38.
Fujii H, Itoh Y, Ohnishi N, Sakamoto M, Ohkawara T, Sawa Y, et al. Relapse of hepatitis C in a pegylated-interferon-alpha-2b plus ribavirin-treated sustained virological responder. Hepatol Res 2010; 40(6): 654–60.
Namikawa M, Kakizaki S, Yata Y, Yamazaki Y, Horiguchi N, Sato K, et al. Optimal follow-up time to determine the sus-tained virological response in patients with chronic hepatitis C receiving pegylated-interferon and ribavirin. J Gastroenterol Hepatol 2012; 27(1): 69–75.
Radkowski M, Gallegos-Orozco JF, Jablonska J, Colby TV, Walew-ska-Zielecka B, Kubicka J, et al. Persistence of hepatitis C virus in patients successfully treated for chronic hepatitis C. Hepa-tology 2005; 41(1): 106–14.
Pham TN, Michalak TI. Occult hepatitis C virus infection and its relevance in clinical practice. J Clin Exp Hepatol 2011; 1(3): 185–9.
Welker M, Zeuzem S. Occult hepatitis C: How convincing are the current data? Hepatology 2009; 49(2): 665–75.
Castillo I, Rodríguez-Iñigo E, López-Alcorocho JM, Pardo M, Bar-tolomé J, Carreño V. Hepatitis C virus replicates in the liver of patients who have a sustained response to antiviral treatment. Clin Infect Dis 2006; 43(10): 1277–83.
Tsuda N, Yuki N, Mochizuki K, Nagaoka T, Yamashiro M, Omura M, et al. Long-term clinical and virological outcomes of chronic hepatitis C after successful interferon therapy. J Med Virol 2004; 74(3): 406–13.
Pawlotsky J. Therapy of hepatitis C: from empiricism to eradi-ca¬tion. Hepatology 2006; 43(2 Suppl 1): 207–20.
Uyanikoglu A, Kaymakoglu S, Danalioglu A, Akyuz F, Ermis F, Pi¬narbasi B, et al. Durability of sustained virologic response in chronic hepatitis C. Gut Liver 2013; 7(4): 458–61.
Marciano S, Borzi SM, Dirchwolf M, Ridruejo E, Mendizabal M, Bes¬sone F, et al. Pre-treatment prediction of response to pegin-ter¬feron plus ribavirin in chronic hepatitis C genotype 3. World J Hepatol 2015; 7(4): 703–9.
Rosen HR. Emerging concepts in immunity to hepatitis C virus infection. J Clin Invest 2013; 123(10): 4121–30.
Larrubia J, Moreno-Cubero E, Miquel J, Sanz-Villalobos E. Hepa-ti¬tis C virus-specific cytotoxic T cell response restoration after treatment-induced hepatitis C virus control. World J Gastro-enterol 2015; 21(12): 3480–91.
Lin A, Thadareddy A, Goldstein MJ, Lake-Bakaar G. Immune sup¬pression leading to hepatitis C virus re-emergence after sustained virological response. J Med Virol 2008; 80(10): 1720–2.
Gordon CE, Balk EM, Becker BN, Crooks PA, Jaber BL, Johnson CA, et al. KDOQI US commentary on the KDIGO clinical practice guideline for the prevention, diagnosis, evaluation, and treatment of hepatitis C in CKD. Am J Kidney Dis 2008; 52(5): 811–25.
Djukanović L, Aksić-Miličević B, Antić M, Baković J, Varga Ž, Go-jaković B, et al. Epidemiology of end-stage renal disease and hemodialysis treatment in Serbia at the turn of the millenni-um. Hemodial Int 2012; 16(4): 517–25.
Cunningham EB, Applegate TL, Lloyd AR, Dore GJ, Grebely J. Mixed HCV infection and reinfection in people who inject drugs: Impact on therapy. Nat Rev Gastroenterol Hepatol 2015; 12(4): 218–30.